SAM
EDIT icon

Smartleaf Asset Management’s Editas Medicine EDIT Stock Holding History

Smartleaf Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320 Hold
100
– – ﹤0.01% 3259
2026
Q1 		$223 Hold
100
– – ﹤0.01% 3327
2025
Q4 		$204 Buy
+100
New +$289 ﹤0.01% 3363
2024
Q3 		– Sell
-23
Closed -$109 – 2928
2024
Q2 		$109 Buy
+23
New +$130 ﹤0.01% 2719

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Smartleaf Asset Management's EDIT Position: Q2 2026 in Review

Smartleaf Asset Management held its Editas Medicine (EDIT) position steady in Q2 2026 at 100 shares worth $320. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Smartleaf Asset Management first reported a position in EDIT in Q2 2024 and has held it in 4 quarters since. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Smartleaf Asset Management held 100 shares of Editas Medicine worth $320 as of Q2 2026.
  • Smartleaf Asset Management left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3259 holding.
  • Smartleaf Asset Management first reported a position in Editas Medicine in Q2 2024 and has held it in 4 quarters since.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.